Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
A phase 2 trial of Plitidepsin in Liposarcoma, run by Institut Bergonié, recorded as terminated on the registry.
Overview
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial is a phase 2 interventional study registered as NCT01876043 by Institut Bergonié, with 24 participants recorded, started 2012-02 and due to reach its primary completion in 2015-04. Interventions recorded: plitidepsin. Conditions recorded: Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma.
Linked to the drug Plitidepsin because the registry names it among its interventions and Liposarcoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Shares Plitidepsin and the tag pipeline.
- TrialAplidin - Dexamethasone in Relapsed/Refractory Myeloma
Shares Plitidepsin and the tag pipeline.
- TrialAPG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Shares Liposarcoma and the tag pipeline.
- TrialSpearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Shares Liposarcoma and the tag pipeline.